The size of the Asia-Pacific platelet-rich plasma market is estimated to be USD 151.86 million by 2026 and USD 72.55 million in 2021, registering a CAGR of 15.92% during the forecast period.
The growing prevalence of orthopedic illnesses, neurological disorders, cardiovascular diseases, sports injuries, and obesity in the Asia Pacific has proved critical in maintaining high demand for platelet-rich plasma. In addition, the advent of improved equipment for greater platelet-rich plasma preparation efficiency is further estimated to accelerate the APAC PRP market.
The treatment is safe and cost-efficient, where the platelets are injected into and around the injured site to speed up the healing process. On the other hand, this procedure does not cause infection or allergy because the patient's blood is also utilized. The growing frequency of orthopedic diseases is expected to increase demand for platelet-rich plasma treatment. Furthermore, the market will also benefit significantly from the increased awareness of platelet-rich plasma treatments and technologies in emerging nations.
A small amount of blood from a human is used in platelet-rich plasma treatment, which uses existing technologies to cure one's illness. In the years ahead, the APAC platelet-rich plasma market is expected to be driven by increased technology usage in various end-use sectors, such as cosmetic surgery.
However, the lack of awareness of the technology and the advancements in the rural areas in developing countries such as India limits the Platelet Rich Plasma Market growth. Furthermore, tissue or nerve damage and allergies in rare conditions impede the market growth due to side effects. Moreover, as these therapies have been more commercialized, their prices have risen. Also, weak reimbursement policies are extremely time-consuming and difficult have difficult processes for getting approvals. This acts as a major obstacle, stifling market growth. In addition, the possibility of treatment failure also limits the market to some extent.
This research report on the APAC platelet-rich plasma market has been segmented and sub-segmented into the following categories:
By Application:
By Product:
By Origin:
By Country:
Geographically, with the growing awareness towards PRP therapy, there is huge potential for the Platelet Rich Plasma market to thrive in the Asia-Pacific region over the next decade. The APAPC Platelet Rich Plasma Market is anticipated to account for a prominent share in the global market during the forecast period. The advent of new application areas for platelet-rich plasma technologies will provide the industry with additional paths to investigate. In addition, the development of technologically improved equipment will benefit the top firms in the Asia Pacific platelet-rich plasma market.
The growing prevalence of orthopedic illnesses, neurological disorders, cardiovascular diseases, sports injuries, and obesity in the Asia Pacific has proved critical in maintaining high demand for platelet-rich plasma. In addition, the advent of improved equipment for greater platelet prosperous plasma preparation efficiency has also boosted the market. The increased awareness of platelet-rich plasma technology in different treatments, rising healthcare spending, and research and development efforts are the main drivers of the market growth.
The growing elderly population in India and the availability of qualified doctors and more awareness will drive up demand for platelet-rich plasma. Therefore, this aspect is anticipated to boost growth in the worldwide platelet-rich plasma market over the forecast period.
Platelet-rich plasma blends modern-day technology with the body's natural capacity to repair itself. As a result, several applications, such as ophthalmology, neurosurgery, and cosmetic surgery, are expanding their platelet-rich plasma, which is expected to drive the Asia-Pacific platelet-rich plasma market.
KEY MARKET PLAYERS:
A few notable companies operating in the Asia-Pacific platelet-rich plasma market profiled in this report are DR. PRP AMERICA, LLC, Glofinn Oy, Zimmer Biomet, DePuy Synthes, Emcyte Corporation, Terumo BCT, Anthrex Inc, T-Biotechnology, and Stryker.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Orthopedics
5.1.3 Cosmetic Surgery
5.1.4 Ophthalmic surgery
5.1.5 Neurosurgery
5.1.6 Y-o-Y Growth Analysis, By Application
5.1.7 Market Attractiveness Analysis, By Application
5.1.8 Market Share Analysis, By Application
5.2 Product
5.2.1 Introduction
5.2.2 Pure
5.2.3 Leukocyte-Rich
5.2.4 Leukocyte-Rich Fibrin
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Origin
5.3.1 Introduction
5.3.2 Homologous PRP
5.3.3 Autologous PRP
5.3.4 Allogeneic PRP
5.3.5 Y-o-Y Growth Analysis, By Origin
5.3.6 Market Attractiveness Analysis, By Origin
5.3.7 Market Share Analysis, By Origin
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product
6.1.3.4 By Origin
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Product
6.1.4.4 By Origin
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Product
6.1.5.4 By Origin
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Zimmer Biomet
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 DR. PRP AMERICA
8.3 LLC
8.4 Gloffin Oy
8.5 Depuy Synthes
8.6 Emcyte Cororation
8.7 Terumbo BCT
8.8 Anthrex Inc
8.9 T-Biotechnology
8.10 Stryker
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
